Pfizer Inc and partner BioNTech SE said on Friday they had applied to the European health regulator to extend the marketing authorization for their coronavirus vaccine for use in adolescents aged 12 to 15.
The companies filed a similar request in the United States earlier this month for the vaccine, which is already authorized for use in people from 16 years of age in both the United States and the European Union.
The submissions are based on positive data from a late-stage clinical trial that enrolled 2,260 participants aged 12 to 15, the companies said.
US Centers for Disease Control and Prevention director Rochelle Walensky told ABC News earlier this month that she expected the vaccine to be authorized for 12- to 15-year-olds by mid-May.
BioNTech expects vaccine trial results for babies, other EMA approvals soonBioNTech expects results by September from trials testing the COVID-19 vaccine that it and Pfizer have developed in babies as young as six months old, ... Coronavirus
BioNTech founder says Europe will reach herd immunity against COVID-19 this summerEurope can achieve herd immunity against the coronavirus within three to four months, the head of German pharmaceutical company BioNTech, which ... Coronavirus
EU seals deal with Pfizer-BioNTech for up to 1.8 bln doses of coronavirus vaccineThe European Union sealed a deal with Pfizer-BioNTech for the supply of up to 1.8 billion doses of their COVID-19 vaccine, an EU official told ... Coronavirus